ロード中...
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
HER2-positive (HER2+) breast cancer accounts for 18%–20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted therapy for breast cancer, established the era of personalized treatment for HE...
保存先:
| 出版年: | Biochim Biophys Acta |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4261073/ https://ncbi.nlm.nih.gov/pubmed/25065528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbcan.2014.07.007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|